Radiolabeled dosing solutions were prepared by mixing the (14)C-radiolabeled tris(1-chloro-2-propyl)phosphate with the non-radiolabeled Fyrol PCF in a vehicle of ethanol, Emulphor and water. Dosing solutions were prepared and analyzed so that rats wou1d receive approximately 0.5 mL (2mL/kg body weight) containing either 20 or 200 mg tris(1-chloro-2propyl) phosphate/kg body weight and 40 uCi of radiolabeled tris(1-chloro-2propyl) phosphate. Two study phases were performed. In the recovery phase animals were dosed and urine, feces and expired air were collected at 11 time intervals over 8 days. At least 5 animals per sex received oral doses of 200 mg/kg, while 5 males each received 20 mg/kg by either a single oral or i.v. administration. In the plasma phase animals were dosed and blood samples, urine and feces were collected at 18 predetermined intervals over 8 days. In both phases, at least 5 animals per sex received oral doses of 200 mg/kg, while 5 males each received 20 mg/kg by either a single oral or i.v. administration. Urine, feces, expired air, tissues and serial blood samples were collected and analyzed for total radioactivity. Metabolites of tris (1-chloro-2-propyl)phosphate were isolated, quantitated, and identified in the urine and feces of rats...Identifiable metabolites accounted for 75-78.5% of urinary and fecal radiocarbon at both doses in both sexes 0,0-[bis(l-chloro-2-propyl)]-0-(2-proprionic acid) phosphate was identified as a major metabolite and accounted for over 50% of the dose in the urine and feces of both sexes at both dose levels.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
毒性数据
大鼠LC50 > 4,600毫克/立方米/4小时
LC50 (rat) > 4,600 mg/m3/4hr
来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases
/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/
/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
解毒与急救
/SRP:/ 高级治疗：对于无意识、严重肺水肿或严重呼吸困难的病人，考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。考虑使用药物治疗肺水肿……。对于严重的支气管痉挛，考虑给予β激动剂，如沙丁胺醇……。监测心率和必要时治疗心律失常……。开始静脉输注D5W /SRP: "保持开放"，最低流量/。如果出现低血容量的迹象，使用0.9%生理盐水（NS）或乳酸林格氏液。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象……。使用地西泮或劳拉西泮治疗癫痫……。使用丙美卡因氢氯化物协助眼部冲洗……。 /Poisons A and B/
/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/
/GENOTOXICITY/ In an initial unscheduled DNA synthesis (UDS) assay, human WI-38 cells blocked in G1 phase were grown in a medium containing Fyrol PCF in DMSO at concentrations of 0.1, 0.5, 1 or 5 uL/mL. In one series, S9 from Arochlor-pretreated rat livers provided the activation system. N-methyl nitroguanidine was used as the positive control in the activation system, while benzo(a)pyrene was used as the positive control in the nonactivated system. A second assay was conducted because Fyrol PCF concentrations above 0.1 uL/mL were too toxic. The second assay employed Fyrol in DMSO at concentrations of 5, 10, 50 and 100 nL/mL...Fyrol PCF was perhaps weakly active at 0.01 uL/mL in activated and nonactivated systems without an associated dose response at higher concentrations.
Radiolabeled dosing solutions were prepared by mixing the (14)C-radiolabeled tris(1-chloro-2-propyl)phosphate with the non-radiolabeled Fyrol PCF in a vehicle of ethanol, Emulphor and water. Dosing solutions were prepared and analyzed so that rats would receive approximately 0.5 mL (2mL/kg body weight) containing either 20 or 200 mg tris(1-chloro-2propyl) phosphate/kg body weight and 40 uCi of radiolabeled tris(1-chloro-2propyl) phosphate. Two study phases were performed. In the recovery phase animals were dosed and urine, feces and expired air were collected at 11 time intervals over 8 days. At least 5 animals per sex received oral doses of 200 mg/kg, while 5 males each received 20 mg/kg by either a single oral or i.v. administration. In the plasma phase animals were dosed and blood samples, urine and feces were collected at 18 predetermined intervals over 8 days. In both phases, at least 5 animals per sex received oral doses of 200 mg/kg, while 5 males each received 20 mg/kg by either a single oral or i.v. administration. Urine, feces, expired air, tissues and serial blood samples were collected and analyzed for total radioactivity... Tris (1-chloro-2-propyl) phosphate and its metabolites were rapidly eliminated following a single bolus dose in male and female rats. ...No difference was observed between sexes or between doses. A biphasic (plasma) elimination followed first order kinetics. While urinary excretion was identified as the primary route of elimination, the extent of elimination was dependent upon the amount administered and the route of administration. This was also true for fecal elimination. Urinary and fecal elimination were sex-independent with eighty-nine percent of the dose being eliminated by 72 hours. Total body burden at the end of eight days was less than 1%...
Radiolabelled (14)C-tris(1-chloro-2-propyl) phosphate (99 % pure by GC) was administered in a single oral dose of 16.4 mg/kg bw (0.05 mmol/kg) in olive oil to groups of 3-5 male Wistar rats. Absorption was calculated from the radioisotopic measurements of cumulative urinary excretion and cumulative exhalation 7 days post-exposure, and of the amount in blood and tissues of rats sacrificed at 3, 6, 12 hours as well as 1, 3 or 7 days following administration. Absorption of radiolabelled TMCPP was rapid. Radiolabel was detected throughout the body as early as 3 hours post-administration. At 7 days, 76 % of the administered oral dose had been excreted in the urine and in expired air or remained in the carcass. Another 22 % was excreted in the feces. TMCPP, however, undergoes enterohepatic circulation and it is not clear if this proportion includes unabsorbed TMCPP, TMCPP excreted in the bile, or both. Therefore, at least 76 % was absorbed following oral administration to rats.
(14)C-labelled TMCPP was administered in a single oral dose of 50 umol/ kg bw in olive oil to male Wistar rats. After 3 hours, the highest concentration of (14)C was found in the liver (29 nmol/g tissue) and the kidney (27 nmol/g tissue) followed by the lung (9 nmol/g tissue). The concentrations in blood, heart, spleen, brain, testis, adipose tissue and muscle were all below 4 nmol/g tissue.
Wistar rats were given 50 umol TMCPP/kg bw orally. Most of the (14)C-labelled TMCPP was excreted within 24 hours and by 7 days, less than 1 % remained in the tissues. Urinary excretion accounted for 67 %, fecal excretion for 22 %, and expired air for 8 % of the label. Also biliary excretion of (14)C-TMCPP was measured in cannulated rats for 48 hours following the same oral dose. Biliary radioactivity peaked within 2 hours of administration and after 48 hour, biliary excretion accounted for approximately 45 % of the administered dose.
into a series of hydroxylated and dechlorinated products. Based on the luminescent bacteria experimental data, the toxicity of TCPP products increased obviously as the reaction proceeded. In conclusion, degradation of high concentration TCPP in UV/H2O2 systems may result in more toxic substances, but its potential application for real wastewater is promising in the future after appropriate optimization
NITROGEN-CONTAINING COMPOUNDS SUITABLE FOR USE IN THE PRODUCTION OF POLYURETHANES
申请人：Evonik Degussa GmbH
公开号：US20180194889A1
公开（公告）日：2018-07-12
The present invention provides for the use of nitrogen compounds of formula (I) and/or of corresponding quaternized and/or protonated compounds for production of polyurethanes, compositions containing these compounds and polyurethane systems, especially polyurethane foams, which have been obtained using the compounds.
Preparation of phosphorus-containing propoxylation products by using aluminium trichloride
申请人：Weiss Thomas
公开号：US20080227997A1
公开（公告）日：2008-09-18
The invention describes a process for preparing propoxylated, phosphorus-containing compounds using aluminium chloride catalyst.
这项发明描述了一种使用氯化铝催化剂制备丙氧基化磷含化合物的方法。
ZINC KETOIMINATE COMPLEXES AS CATALYSTS FOR THE PRODUCTION OF POLYURETHANES
申请人：Evonik Operations GmbH
公开号：US20200216474A1
公开（公告）日：2020-07-09
The use of zinc ketoiminate complexes in the production of polyurethanes is described, wherein the zinc ketoiminate complexes are obtainable by reacting a zinc compound with certain ketimines.
